AMSBIO, the life sciences reagent supplier now operating as part of the Europa Biosite group following its acquisition in October 2024, has launched an expanded range of authenticated cell lines comprising more than 1,000 independently verified human and animal lines. The catalog spans a wide range of tumors, tissues, primary cells, and stem cells, with each line subjected to a rigorous multi-step authentication process before it reaches the researcher.
The new range is available now. Researchers can access the full catalog at amsbio.com/products/cells-cell-culture/cell-lines or contact AMSBIO directly at info@amsbio.com.
What the Expanded Catalog Includes and Why Authentication Matters
The scale of the problem AMSBIO's authentication program is designed to address is well documented. A 2017 investigation found more than 30,000 published studies may be compromised by misidentified cell lines (Horbach & Halffman, PLOS ONE, 2017), and peer-reviewed analysis published in the EMBO Journal in 2022 found that at least 5% of human cell lines submitted for publication were misidentified (Souren et al., 2022, doi:10.15252/embj.2022111307). Cross-contamination, mislabeling during passage, and the unchecked proliferation of rapidly dividing lines through slower-growing cultures are the most common culprits. The cost to reproducible science is substantial: one estimate placed the annual U.S. cost of irreproducible preclinical research at $28 billion, with misidentified cell lines a significant contributing factor (reported in Lab Manager).
AMSBIO's approach centers on independent verification at the source, before a line is cataloged or shipped. Each cell line in the expanded range undergoes:
- Short tandem repeat (STR) profiling for human cell line identity confirmation
- Species verification for animal-derived lines
- Comprehensive sterility testing
- Mycoplasma testing, using PCR-based methods capable of detecting fewer than five mycoplasma genome copies per microliter of sample
- Detailed passage documentation to support traceability and reproducibility
The result is a catalog in which researchers can confirm not just what they ordered, but that the genetic composition and phenotypic characteristics of the line match the original source material, and have been maintained through each documented passage.
A Broad Coverage of Research Models
The more than 1,000 verified lines span a range deliberately chosen to reflect the breadth of current cell-based research needs. Coverage includes:
- Human and animal tumor-derived lines across a wide range of cancer types
- Normal tissue lines for comparative and mechanistic work
- Primary cells, which retain more physiologically relevant characteristics than established immortalized lines
- Stem cells, including options supported by AMSBIO's StemFit media and iMatrix recombinant laminin infrastructure
Cell lines are used in the study of gene activation, protein-protein interactions, cell signaling, and differentiation, and they provide a more physiologically relevant model than cell-free assays for a wide range of research applications. For lab managers selecting models for drug discovery, toxicology, or mechanism-of-action studies, the breadth of this catalog reduces the need to source from multiple vendors, each with different authentication standards.
Maintaining reproducibility across biological reagents, and cell lines in particular, requires stringent qualification and tracking at the point of sourcing. As Lab Manager has noted in its coverage of reproducibility in biological research, a change in cell line lot or vendor can fundamentally alter experimental outcomes, making documentation of supplier authentication processes a core part of sound reagent management.
Advanced Lab Management Certificate
The Advanced Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
AMSBIO's Position Within Europa Biosite
AMSBIO was founded in 1987 by Alex Sim, who remains a senior advisor at Europa Biosite following the acquisition. The company, headquartered in Abingdon, Oxfordshire, with offices in the United States and the Netherlands, built its reputation across biospecimens, stem cell research, 3D cell culture, glycobiology, and molecular biology over nearly four decades. Its integration into Europa Biosite, a life sciences distributor now majority-owned by EQT Healthcare Growth, has expanded its reach across 17 countries in Europe and North America.
The Europa Biosite group comprises seven companies, including AMSBIO, Biomol, Cambridge Bioscience, LubioScience, Nordic Biosite, Sanbio, and Szabo-Scandic, with AMSBIO's biorepository of human and animal specimens strengthening the group's biospecimen portfolio. The group reported a five-fold increase in sales over the five years preceding the Adelis Equity-era acquisitions.
For the purposes of this cell line expansion, AMSBIO's long-standing expertise in GMP-grade stem cell infrastructure and biospecimen handling gives it a credible position in the authenticated cell line market, where the combination of scientific rigor and supply chain reliability is the core differentiator.
Interested in life sciences?
What This Means for Your Lab
For lab managers procuring cell lines for regulated or publication-driven research, the key question is not just which lines are available, but what verification evidence comes with each one. AMSBIO's catalog documentation covers passage history, authentication method, sterility status, and mycoplasma test results, giving research teams the traceability records they need to satisfy institutional biosafety requirements, journal authentication policies, and internal QC standards.
An increasing number of journals now require cell line authentication data at submission, and funding bodies are beginning to follow. Sourcing from a vendor whose authentication is conducted independently, rather than relying on the researcher to perform post-receipt testing, reduces both the burden on lab staff and the risk of a reproducibility failure downstream. For labs working across multiple species or tumor types, a single authenticated source for more than 1,000 lines also simplifies vendor management considerably.
Full details and the complete catalog are available at amsbio.com/products/cells-cell-culture/cell-lines. AMSBIO can also be reached by phone at +1-617-945-5033 (US), +44-1235-828200 (UK), or +31-72-8080244 (EU), or by email at info@amsbio.com.
